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Epidermolytic hyperkeratosis (EHK), (bullous congenital ichthyoslform erythroderma), Is an autosomal dominant
human skin disorder. Recently, we and others have described mutations in keratins 1 and 10 (K1 and K10) In
patients with this disease. Structure-function models predict that these mutations would impair normal filament
assembly and function. We have extended our earlier studies to include 8 more Incidences of EHK. In half of
these families, we were unable to locate a mutation within the rod domains of either K1 or K10. However,
polymorphic restriction site and sequence analysis of the other families revealed a mutational hot spot within
the 1A alpha-helical segment of K10. These involve Arginlne to Hlstldlne, Arglnlne to Cystelne and Arglnlne to
Leucine substitutions at residue 10 of the rod domain. Interestingly, mutations In the corresponding Arglnine
residue in keratin K14 have been Identified In patients with epidermolysis bullosa simplex. The large number
of mutations found at this position in both keratins K10 and K14 suggests that other eplthelia cell disorders will
be discovered that are caused by the corresponding mutation in related type I keratin genes.
Epidermolytic Hyperkeratosis (EHK), (bullous congenital
ichthyosiform erythroderma), is a genetic human skin disorder
transmitted in an autosomal dominant mode with little
intrafamilial phenotypic variation (McKusick # 11380 (1)). At
birth, affected individuals usually show erythroderma and
widespread blistering of the skin. With age, the erythroderma
resolves, blistering diminishes and hyperkeratotic lesions become
the prominent feature (2). Blistering and erythroderma are mostly
absent in adults but can occur as transitory events after physical
trauma, stress or treatment with retinoids. The incidence of this
disease is estimated at 1 in 200,000 in the United States (3).
Histopathology is characterized by cytolysis and intra-epidermal
cleavage in the suprabasal layers and a broadening of the granular
and stratum corneum layers (4,5). The ultrastructural hallmark
of EHK is the appearance of a collapsed keratin filament network
with clumps and aggregates of the tonofilaments surrounding the
nucleus in the spinous and granular cells of the epidermis (6,7).
Ultrastructural studies have long implicated a defect in the
differentiation-specific keratins, Kl and K10 as the cause of the
disease (6-9). Moreover, several studies have linked the disease
to the type II keratin loci on chromosome 12q (10—12). Recently,
we and others have described mutations in highly conserved
regions of Kl and K10 in patients with this disease (13-15).
Structure function models, as well as in vitro mutagenesis
experiments, predict that these mutations would impair normal
filament assembly leading to a collapse of the filament network
and clumping of the tonofilaments around the nucleus (reviewed
in 13).
Most of the mutations (5 out of 6) causing EHK that have been
identified to date occur within highly conserved sequence motifs
at the beginning and end of the rod domain of these keratins (see
Fig. 3). Here, we report four more independent families with
EHK that harbor mutations in K10. All of these involved
substitutions of thearginine residue at position 10 of the 1A
domain. In one of the families (EHK-E/S), the disease can be
traced back four generations and in the other cases (EHK-A,
EHK-K, EHK-D), the mutations were sporadic. The affected
individual of the EHK-A family exhibits hyperkeratosis with little
or no blistering, even as a child. Most involvement is on the
dorsal side of feet and lower extremities with minimal
involvement on the backs of hands or neck. There is no
involvement of the palms and soles. The face and scalp are clear
with normal hair and nails. The affected individual of the EHK-K
family suffers from a more generalized expression of the disease.
He exhibits hyperkeratosis with blistering and occasional
secondary pyroderma over the face, scalp, neck, trunk and
extremities as well as hyperkeratosis without blistering of palms
and soles. Likewise, the affected individual of the EHK-D family
also suffers from massive, generalized hyperkeratoses over the
face, scalp, neck, trunk, and extremities, including the palms
and soles. All affected members of the EHK-E/S family show
generalized involvement of the entire integument, with marked
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Figure 1. (A) Pedigree and PCR analysis of the EHK-E/S family. Males are
represented by squares, females by circles and affected individuals by solid
symbols. K10 oligonucleotide primers and PCR conditions are as previously
described (13). PCR products were digested with Aci I (New England Biolabs,
Beverly, MA). (B) Sequence of the beginning of the 1A segment of HK10. The
amino acid residues are numbered with respect to the start of the rod domain
(13). The arginine at position 10 in this sequence corresponds to residue 156
in K10 (22) and residue 125 in the basal cell type I keratin, K14 (24). The Aci
I recognition sequence is boxed and the three substitutions resulting in the loss
of this site are indicated.
hyperkeratosis of the scalp, trunk, extremities, backs of hands
and feet but sparing the palms and soles. Hair and nails are
normal. The individual denoted as 1.2 in this pedigree (Figure 1 A)
appears to have been the spontaneous new mutation, according
to information supplied by her spouse and son. A complete
clinical description and ultrastructural data from the EHK-E/S
proband have been reported elsewhere (7,16).
These mutations were initially identified by Aci I digest of a
polymerase chain reaction (PCR) fragment that spans the 1A
segment of K10 (Figure 1A, and data not shown). The Aci I
recognition sequence includes the arginine codon at position 10
of the rod domain (Figure IB). The specific mutations were
subsequently identified by direct DNA sequencing (Figure 2)
using the protocol described previously (13). The PCR product
generated by these primers is 315 base pairs (bp) long and after
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Figure 2. Direct sequencing of PCR products spanning the 1A region of K10
from the EHK-K and EHK-D probands. PCR and sequencing primers are listed
in reference 13. Normal, sequence obtained from an unaffected family member.
Hetero, sequence from the affected individual. (A) Sequence of the 1A segment
of K10 from die EHK-K proband. The C - T transition is indicated by the arrow
and results in rhe expression of a cysteine residue at position 10 of the rod domain.
(B) Sequence of the 1A segment of K10 from the EHK-D proband. The G - T
transversion is indicated and results in the expression of a leucine residue at position
10 of the rod domain.
digestion with Aci I, the wild type sequence is cut into a 255
bp and a 60 bp fragment. Patients are heterozygous for the mutant
allele and therefore exhibit three fragments in this assay. As can
be seen from Figure 1, the Aci I restriction site polymorphism
co-segregates with the expression of the disease. Unaffected
family members all exhibited the wild type sequence at this site.
Moreover, a survey of this site by Cheng et al (14) showed no
polymorphisms in a sample of 103 unaffected individuals.
Sequence analysis of affected individuals in both the EHK-E/S
and EHK-A families revealed a histidine substitution at position
10 of the 1A segment (data not shown). This same substitution
has already been reported in three other unrelated incidences of
EHK (13,14) and interestingly, in the corresponding position
within K14 in a patient with epidermolysis bullosa simplex (EBS)
(17). Keratin K14 is the basal cell homolog of the suprabasal
keratin, K10. The EHK-K proband harbors a cysteine substitution
at this position (Figure 2A). Although this is the first report of
this mutation for EHK, the same substitution has been observed
in K14 in a patient with EBS (17). The EHK-D proband shows
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Figure 3. Schematic showing the positions of mutations reported to date for the keratin skin diseases, EBS and EHK. The conserved sequence motifs at the beginning
of the 1A segment and at the end of the 2B segment are indicated by hatched and solid boxes, respectively. Data compiled from the present study and: [a] Kl,
L17 to P, (HI subdomain) EHK, Chipev et al 1992 (15); [b] K14, Rio to C/H, EBS, Coulombe et al 1991 (17); K10, R10 to H, (two incidences) EHK, Cheng
et al 1992 (14); K10, R10 to H, EHK, Rothnagel et al 1992 (13); [c] K10, L13 to S, EHK, Rothnagel et al 1992 (13); [d] K14, E29 to A, EBS, Hovnanian et al
1993 (25); [e] K14, M'«" to R, EBS, Humphries et al 1993 (26); [f] K14, L272 to P, EBS, Bonifas et al 1991 (27); [g] K5, L295 to P, EBS, Dong et al 1993 (28);
[h] K5, E307 to G, EBS, Lane et al 1992 (29); [i] Kl, E310 to Q, EHK, Rothnagel et al 1992 (13). "Residues are numbered with respect to the HI subdomain
or to the beginning of the rod domain.
an arginine to leucine substitution at this position which is the
first report of this substitution in a keratin gene (Figure 2B).
The complete segregation of these arginine mutations with the
expression of the disease (this study and refs. 13, 14, 17) coupled
with the complete absence of polymorphic variations at this site
in unaffected individuals (14) suggests that mutations of this
arginine residue are fully penetrant for the disease. It has been
observed however, that the first sporadic incidence of EHK in
a family may present a less severe clinical picture than their
offspring, but never vice-versa, and is attributable to gonadal
mosaicism rather than to variable expression of the disease (18).
Although it remains to be demonstrated in transgenic studies that
the mutations described above are causal, in vitro studies have
implicated this arginine residue as critical to filament integrity.
The same arginine to histidine substitution in human lamin A
was found to destabilize the nuclear lamin filament network (19)
and the cysteine mutation in the corresponding position in K14
disrupted the keratin filament network when transfected into
cultured keratinocytes (17).
Sequence analysis of the other four families did not reveal any
mutations within the rod domains of Kl and K10 in affected
individuals. Interestingly, Cheng et al., 1992 (14) also failed to
find the genetic defect in another four cases of EHK. This
suggests that the causative mutations in these patients reside
outside the rod domain of Kl and K10 or alternatively, that these
individuals harbor mutations in other suprabasally expressed
keratins, such as K2 (20). Remarkably, three other unrelated
incidences of EHK and two of EBS involve substitutions of the
arginine residue at position 10 of the rod domain (Figure 3). By
comparison, no other position has been associated to date with
more than one incidence of mutation. This suggests that this
residue is a hot spot for mutations in both K10 and K14 and we
predict for other type I keratins as well.
A plausible explanation for the apparent sensitivity of this
arginine residue to mutation is that its codon contains a CpG
dinucleotide on both coding and non-coding strands. The CpG
dinucleotide is acted upon by eukaryotic methylases and
subsequent deamination of the methylated cytosine will generate
a C to T transition (see 14 and refs. therein). Moreover, an
increased frequency of transversions have also been observed at
these sites (21). CpG dinucleotides also occur at other similarly
crucial sites within the rod domain of these keratins such as in
the codon for the arginine residue at position 304 of K10, located
within the highly conserved TYRXLLEGE motif (22) at the end
of the rod domain. In spite of the fact that this region has been
extensively analyzed (see Figure 3), not a single mutation has
been reported at this residue to date, although in vitro data (19,23)
have shown that it is critical for filament function. This suggests
that other factors, such as the degree of methylation, may be
involved in determining the mutational hot spot observed at the
arginine residue (R10) within the rod domain of type I keratins.
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